Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sosei Names New CEO

Executive Summary

Japanese biopharma Sosei Group Corporation has appointed Peter Bains representative executive officer and CEO, taking over from founder Shinichi Tamura, who has been appointed representative executive officer and executive chair. Bains joins the company from Syngene International Ltd., where he was executive director and CEO. Prior to this, he held leadership positions at several businesses, including Heptares Therapeutics Ltd and GlaxoSmithKline PLC. (Also see "Heptares-Powered Sosei's Incoming CEO Explains What Happens Next" - Scrip, 28 Apr, 2016.)

You may also be interested in...



Heptares-Powered Sosei's Incoming CEO Explains What Happens Next

Japanese company Sosei conducted a master stroke last year when it acquired UK biotechnology company Heptares as its in-house R&D engine. Deal after quality deal has ensued, and Sosei's share price has rocketed by more than 400%. Scrip's Sukaina Virji spoke to Sosei's COO – and CEO-elect – Peter Bains to find out what happens next.

Executives On The Move: CEOs Named At Kaleido Biosciences, DewPoint Therapeutics And WntResearch AB

New chief business officer named at Ovoca Bio, and a new chairman at Opthea Ltd.

Coronavirus Update: No Mortality Gains From Remdesivir In WHO Trial, Gilead Questions Results

Plus Sanofi and Translate Bio release preclinical data from their COVID-19 vaccine candidate, another entrant to the now crowded mRNA vaccine field.

Topics

UsernamePublicRestriction

Register

OM006764

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel